(Q81099047)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

chronic myeloid leukemia

1 reference

1 reference

8

Frye B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Buesche G

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ganser A

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Schlegelberger B

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

von Neuhoff N

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Gadzicki D

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Hecker H

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Bock O

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Kreipe H

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

6 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

2420-2427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17805334%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404917

5 January 2020

exact match

0 references

cites work

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

The histopathology of chronic myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre-staining processing of bone marrow biopsies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404917

7 January 2021